Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.

Cisplatin (cis-diamminedichloroplatinum, CDDP) is one of the most used drugs for osteosarcoma chemotherapy. By using a series of CDDP-resistant variants, which were established from the U-2OS and Saos-2 human osteosarcoma cell lines, we found that CDDP resistance was mainly associated with the increase of both the intracellular level and enzymatic activity of glutathione S-transferase P1 (GSTP1). On the basis of these findings, we evaluated the clinical effect of GSTP1 in a series of 34 high-grade osteosarcoma patients and we found that the increased expression of GSTP1 gene was associated with a significantly higher relapse rate and a worse clinical outcome. These indications prompted us to assess the in vitro effectiveness of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX), a promising new anticancer agent that is a highly efficient inhibitor of GSTP1. NBDHEX was tested on a panel of 10 human osteosarcoma cell lines and 20 variants of the U-2OS or Saos-2 cell lines that were resistant to CDDP, doxorubicin, or methotrexate. NBDHEX proved to be very active on the vast majority of these cell lines, including those with higher GSTP1 levels and enzymatic activity. Drug combination studies showed that NBDHEX can be used in association with CDDP and provided useful information about the best modality of their combined administration. In conclusion, our findings show that GSTP1 has a relevant effect for both CDDP resistance and clinical outcome of high-grade osteosarcoma and that targeting GSTP1 with NBDHEX may be considered a promising new therapeutic possibility for osteosarcoma patients who fail to respond to conventional chemotherapy.

[1]  T. Koji,et al.  Doxorubicin‐induced DNA intercalation and scavenging by nuclear glutathione S‐transferase π , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  L. Ghibelli,et al.  Proapoptotic activity of new glutathione S-transferase inhibitors. , 2005, Cancer research.

[3]  A. Molinari,et al.  A Strong Glutathione S-Transferase Inhibitor Overcomes the P-glycoprotein-mediated Resistance in Tumor Cells , 2006, Journal of Biological Chemistry.

[4]  L. Schumaker,et al.  Advances in Brief Glutathione S-Transferase Amplification is Associated with Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines and Primary Tumors , 2003 .

[5]  H. Tanke,et al.  New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy , 2000, JBIC Journal of Biological Inorganic Chemistry.

[6]  T. Tan,et al.  Mitogen-activated protein kinases in cell-cycle control , 2007, Cell Biochemistry and Biophysics.

[7]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[8]  I. Viano,et al.  A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. , 1999, Molecular pharmacology.

[9]  S. Kohno,et al.  Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. , 1999, Free radical research.

[10]  R. Motzer,et al.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.

[11]  D. Mangham,et al.  Role of glutathione in cisplatin resistance in osteosarcoma cell lines , 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[12]  J. Hayes,et al.  Glutathione S‐transferases , 2002 .

[13]  A. Monks,et al.  Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. , 1996, Molecular pharmacology.

[14]  S. Ferrari,et al.  Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma , 2007, Current opinion in oncology.

[15]  H. Jörnvall,et al.  Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W B Jakoby,et al.  Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. , 1974, The Journal of biological chemistry.

[17]  L. Worth,et al.  Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells , 2007, Molecular Cancer Therapeutics.

[18]  P. Lollini,et al.  Redundancy of autocrine loops in human osteosarcoma cells , 1999, International journal of cancer.

[19]  D. Townsend,et al.  The role of glutathione-S-transferase in anti-cancer drug resistance , 2003, Oncogene.

[20]  P. Picci,et al.  Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  P. Lollini,et al.  Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. , 1993, Anticancer research.

[22]  L. Kèlland,et al.  Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status. , 2007, Biochemical pharmacology.

[23]  R. Gorlick,et al.  Chemotherapy resistance in osteosarcoma: current challenges and future directions , 2006, Expert review of anticancer therapy.

[24]  Giovanni Antonini,et al.  7-Nitro-2,1,3-benzoxadiazole Derivatives, a New Class of Suicide Inhibitors for Glutathione S-Transferases , 2005, Journal of Biological Chemistry.

[25]  K. Hess,et al.  Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  P. Picci,et al.  4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients. , 2005, European journal of cancer.

[27]  T. Ishida,et al.  Overexpression of resistance‐related proteins (metallothioneins, glutathione‐S‐transferase π, heat shock protein 27, and lung resistance‐related protein) in osteosarcoma , 1997, Cancer.